187 related articles for article (PubMed ID: 15287383)
1. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.
Kohno S; Masaoka T; Yamaguchi H; Mori T; Urabe A; Ito A; Niki Y; Ikemoto H
Scand J Infect Dis; 2004; 36(5):372-9. PubMed ID: 15287383
[TBL] [Abstract][Full Text] [Related]
2. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis.
Tabata K; Katashima M; Kawamura A; Kagayama A; Kohno S
Eur J Drug Metab Pharmacokinet; 2006; 31(2):123-8. PubMed ID: 16898081
[TBL] [Abstract][Full Text] [Related]
4. [Antifungal activity and clinical efficacy of micafungin sodium (Funguard)].
Ikeda F
Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):339-44. PubMed ID: 14501170
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.
de Wet NT; Bester AJ; Viljoen JJ; Filho F; Suleiman JM; Ticona E; Llanos EA; Fisco C; Lau W; Buell D
Aliment Pharmacol Ther; 2005 Apr; 21(7):899-907. PubMed ID: 15801925
[TBL] [Abstract][Full Text] [Related]
6. [Antifungal activity and clinical efficacy of micafungin (funguard)].
Ikeda F
Nihon Ishinkin Gakkai Zasshi; 2005; 46(4):217-22. PubMed ID: 16282962
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent.
Pettengell K; Mynhardt J; Kluyts T; Lau W; Facklam D; Buell D;
Aliment Pharmacol Ther; 2004 Aug; 20(4):475-81. PubMed ID: 15298643
[TBL] [Abstract][Full Text] [Related]
8. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation.
Sirohi B; Powles RL; Chopra R; Russell N; Byrne JL; Prentice HG; Potter M; Koblinger S
Bone Marrow Transplant; 2006 Jul; 38(1):47-51. PubMed ID: 16715107
[TBL] [Abstract][Full Text] [Related]
9. Micafungin (Mycamine) for fungal infections.
Med Lett Drugs Ther; 2005 Jun; 47(1211):51-2. PubMed ID: 15961968
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.
Ikeda F; Wakai Y; Matsumoto S; Maki K; Watabe E; Tawara S; Goto T; Watanabe Y; Matsumoto F; Kuwahara S
Antimicrob Agents Chemother; 2000 Mar; 44(3):614-8. PubMed ID: 10681327
[TBL] [Abstract][Full Text] [Related]
12. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.
Denning DW; Marr KA; Lau WM; Facklam DP; Ratanatharathorn V; Becker C; Ullmann AJ; Seibel NL; Flynn PM; van Burik JA; Buell DN; Patterson TF
J Infect; 2006 Nov; 53(5):337-49. PubMed ID: 16678903
[TBL] [Abstract][Full Text] [Related]
13. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
14. Micafungin.
Carver PL
Ann Pharmacother; 2004 Oct; 38(10):1707-21. PubMed ID: 15340133
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of micafungin for chronic pulmonary aspergillosis.
Izumikawa K; Ohtsu Y; Kawabata M; Takaya H; Miyamoto A; Sakamoto S; Kishi K; Tsuboi E; Homma S; Yoshimura K
Med Mycol; 2007 May; 45(3):273-8. PubMed ID: 17464848
[TBL] [Abstract][Full Text] [Related]
16. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
17. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.
Ostrosky-Zeichner L; Kontoyiannis D; Raffalli J; Mullane KM; Vazquez J; Anaissie EJ; Lipton J; Jacobs P; van Rensburg JH; Rex JH; Lau W; Facklam D; Buell DN
Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):654-61. PubMed ID: 16261306
[TBL] [Abstract][Full Text] [Related]
18. Micafungin: a therapeutic review.
Higashiyama Y; Kohno S
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200
[TBL] [Abstract][Full Text] [Related]
19. Micafungin: a new echinocandin.
Chandrasekar PH; Sobel JD
Clin Infect Dis; 2006 Apr; 42(8):1171-8. PubMed ID: 16575738
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
